The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
May 1, 2014, 00:00 AM
10.1016/j.jval.2014.03.523
https://www.valueinhealthjournal.com/article/S1098-3015(14)00574-9/fulltext
Section Title :
Cancer
Section Order :
1580
First Page :
A90
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00574-9&doi=10.1016/j.jval.2014.03.523